Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XL281 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | XL281 administered once a day |
| Arm 2 | EXPERIMENTAL | XL281 administered twice a day |
| Arm 3 | EXPERIMENTAL | XL281 administered once a day. Subjects in this arm will be dosed under fed conditions, fasted conditions, and with a concomitant single dose of 40 mg famotidine, during the second, third, and fourth week of the first cycle. |
| Name | Type | Description |
|---|---|---|
| XL281 | DRUG | Gelatin capsules supplied as 5-, 25-, and 100-mg strengths |
| famotidine | DRUG | single dose, supplied as 20-mg or 40-mg tablets |
Key Inclusion Criteria: * The subject has a histologically confirmed solid tumor that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no therapies known to prolong survival. Subjects treated at the MTD (onc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
XL281 is an investigational small molecule being studied for the treatment of cancer, including non-small-cell lung cancer, colorectal cancer, papillary thyroid cancer, and melanoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
XL281 is being developed by Exelixis, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol EXEL. The company is conducting clinical research to evaluate the safety and efficacy of this investigational oncology drug.
XL281 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
XL281 has been studied in one clinical trial, identified as NCT00451880, titled 'Study of XL281 in Adults With Solid Tumors.' This Phase 1 trial enrolled 180 participants and was completed in the United States. The trial included patients with various solid tumors.
XL281 is the primary name for this investigational drug. No alternative names have been reported for this compound in clinical development.